Sensitivity of the Mantoux Test for Tuberculosis
The Mantoux tuberculin skin test has approximately 70–80% sensitivity for detecting latent tuberculosis infection in immunocompetent individuals, but this sensitivity is significantly compromised in immunocompromised patients and varies substantially based on the chosen cut-off threshold. 1, 2
Sensitivity in Immunocompetent Populations
In culture-confirmed active tuberculosis cases, the Mantoux test demonstrates approximately 77–80% sensitivity when using standard interpretation criteria. 3, 4
Among close contacts of infectious tuberculosis cases, the tuberculin skin test achieves 100% sensitivity when using purified protein derivative (PPD) as the antigen, though this comes at the cost of reduced specificity (72%). 5
Sensitivity varies directly with the chosen cut-off threshold: at ≥5 mm induration the sensitivity reaches 98%, at ≥10 mm it drops to approximately 88–90%, and at ≥15 mm it falls further to only 46–61%. 1, 6
Sensitivity in Immunocompromised Populations
The tuberculin skin test has markedly reduced sensitivity in immunosuppressed individuals, including those with HIV infection, those receiving corticosteroids or TNF-α inhibitors, patients with chronic renal insufficiency, and those with rheumatoid arthritis. 1
The mechanism of reduced sensitivity involves direct inhibitory effects of immunosuppressive drugs on cytokine signaling, antigen-presenting cells, and T-cell proliferation, as well as altered expression of costimulatory molecules. 1
In HIV-infected patients, low CD4 T-cell counts and high frequencies of regulatory T-cells directly correlate with skin test anergy, further compromising sensitivity. 1
Impact of BCG Vaccination on Test Interpretation
BCG vaccination does not reduce the sensitivity of the Mantoux test—it affects specificity by causing false-positive results, not false-negative results. 1
The tuberculin skin test remains a valid screening tool in BCG-vaccinated individuals, and a positive result (≥10 mm in most cases, ≥5 mm in high-risk groups) should be interpreted as evidence of true M. tuberculosis infection, especially in persons from high-TB-prevalence regions. 7
BCG vaccination given in infancy has minimal impact on TST results after ≥10 years, whereas BCG given after infancy can cause false-positive results for up to 55 years. 7
Comparative Performance with IGRAs
Interferon-gamma release assays (IGRAs) demonstrate superior sensitivity compared to the tuberculin skin test, particularly in immunocompromised populations, though large head-to-head studies are still lacking. 1
In one comparative study, ELISPOT showed 88% sensitivity, ELISA 76%, and tuberculin skin test 70% for detecting latent tuberculosis infection. 1
The ELISpot format of IGRA is significantly more sensitive than the tuberculin skin test for active tuberculosis, while the ELISA format shows similar sensitivity. 2
Critical Clinical Pitfalls
Do not dismiss a positive tuberculin skin test as "only BCG" in individuals from high-TB-prevalence settings or with known TB exposure—treat it as evidence of true infection. 7
The tuberculin skin test cannot distinguish active tuberculosis from latent infection—both conditions produce positive results, necessitating chest radiography and clinical evaluation to exclude active disease. 1, 3
Repeated tuberculin skin tests can "boost" waning immune responses, producing false conversions that do not reflect new infection; this is particularly relevant in serial testing programs. 7, 8
In immunocompromised patients, a negative tuberculin skin test cannot reliably exclude tuberculosis infection due to the high rate of anergy; clinical judgment and consideration of IGRA testing are essential. 1, 3
Optimal Testing Strategy
For BCG-vaccinated individuals, IGRAs are preferred over tuberculin skin testing because they achieve approximately 99% specificity compared to only 85% for TST, while maintaining equivalent or superior sensitivity. 8, 3, 2
A two-step approach—initial tuberculin skin test followed by confirmatory IGRA if positive—is endorsed by CDC, NICE, and Swiss guidelines to maximize specificity while preserving sensitivity in BCG-vaccinated populations. 1, 8
In severely immunocompromised patients at highest risk for progression, dual testing (IGRA + TST) may increase sensitivity, though this reduces specificity. 3